Kaw River Care And Rehab | |
750 Blake Street, Edwardsville, Kansas 66111 | |
(913) 422-5832 | |
Name | Kaw River Care And Rehab |
---|---|
Location | 750 Blake Street, Edwardsville, Kansas |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 45 |
Occupancy Rate | 81.33% |
Medicare ID (CCN) | 175219 |
Legal Business Name | Kaw River Operator, Llc |
Ownership Type | For Profit - Corporation |
NPI Number | 1437708427 |
Organization Name | KAW RIVER OPERATOR, LLC |
Address | 750 Blake St, Edwardsville, KS 66111 |
Phone Number | 913-422-5832 |
News Archive
PCI Biotech reported today that it has completed the treatment of the third dose group in the phase I/II study of its proprietary photosensitiser Amphinex® used in combination with the cytotoxic agent bleomycin in cancer patients.
The governing Board of the California Institute for Regenerative Medicine has approved a trio of awards, totaling approximately $4 million, to University of California San Diego School of Medicine researchers to advance studies of new stem cell-based treatments for multiple types of cancer and amyotrophic lateral sclerosis (ALS).
A study published in this week's Proceedings of the National Academy of Sciences identified the molecule that binds to a receptor (a molecule on the cell surface that triggers a reaction within the cell) in the brain that is known to regulate blood pressure and release of insulin.
Responding to the announcement by Health Secretary, John Reid, that £95m will be made available to reward GPs for using the new "choose and book" system, Dr Richard Vautrey, the BMA's GP negotiator with responsibility for IT said:
› Verified 2 days ago
NPI Number | 1487101267 |
Organization Name | KAW RIVER CARE AND REHABILITATION CENTER, LLC |
Address | 750 Blake St, Edwardsville, KS 66111 |
Phone Number | 913-422-5832 |
News Archive
PCI Biotech reported today that it has completed the treatment of the third dose group in the phase I/II study of its proprietary photosensitiser Amphinex® used in combination with the cytotoxic agent bleomycin in cancer patients.
The governing Board of the California Institute for Regenerative Medicine has approved a trio of awards, totaling approximately $4 million, to University of California San Diego School of Medicine researchers to advance studies of new stem cell-based treatments for multiple types of cancer and amyotrophic lateral sclerosis (ALS).
A study published in this week's Proceedings of the National Academy of Sciences identified the molecule that binds to a receptor (a molecule on the cell surface that triggers a reaction within the cell) in the brain that is known to regulate blood pressure and release of insulin.
Responding to the announcement by Health Secretary, John Reid, that £95m will be made available to reward GPs for using the new "choose and book" system, Dr Richard Vautrey, the BMA's GP negotiator with responsibility for IT said:
› Verified 2 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
PCI Biotech reported today that it has completed the treatment of the third dose group in the phase I/II study of its proprietary photosensitiser Amphinex® used in combination with the cytotoxic agent bleomycin in cancer patients.
The governing Board of the California Institute for Regenerative Medicine has approved a trio of awards, totaling approximately $4 million, to University of California San Diego School of Medicine researchers to advance studies of new stem cell-based treatments for multiple types of cancer and amyotrophic lateral sclerosis (ALS).
A study published in this week's Proceedings of the National Academy of Sciences identified the molecule that binds to a receptor (a molecule on the cell surface that triggers a reaction within the cell) in the brain that is known to regulate blood pressure and release of insulin.
Responding to the announcement by Health Secretary, John Reid, that £95m will be made available to reward GPs for using the new "choose and book" system, Dr Richard Vautrey, the BMA's GP negotiator with responsibility for IT said:
› Verified 2 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 1 |
Total Amount of Fines in Dollars | $13328 |
Number of Payment Denials | 0 |
Total Number of Penalties | 1 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 21.85 | 14.46 |
Percentage of long-stay residents who lose too much weight | 2.52 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 25.76 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 1.54 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 6.82 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 2.21 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 72.06 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 40.54 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 29.31 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 2.7 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 18.9 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 48 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 8.82 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 89.81 | 95.98 |
Percentage of short-stay residents who made improvements in function | 64.76 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 13.33 | 82.93 |
News Archive
PCI Biotech reported today that it has completed the treatment of the third dose group in the phase I/II study of its proprietary photosensitiser Amphinex® used in combination with the cytotoxic agent bleomycin in cancer patients.
The governing Board of the California Institute for Regenerative Medicine has approved a trio of awards, totaling approximately $4 million, to University of California San Diego School of Medicine researchers to advance studies of new stem cell-based treatments for multiple types of cancer and amyotrophic lateral sclerosis (ALS).
A study published in this week's Proceedings of the National Academy of Sciences identified the molecule that binds to a receptor (a molecule on the cell surface that triggers a reaction within the cell) in the brain that is known to regulate blood pressure and release of insulin.
Responding to the announcement by Health Secretary, John Reid, that £95m will be made available to reward GPs for using the new "choose and book" system, Dr Richard Vautrey, the BMA's GP negotiator with responsibility for IT said:
› Verified 2 days ago
Edwardsville Care And Rehab Location: 751 Blake Street, Edwardsville, Kansas 66111 Phone: (913) 441-1900 |